Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation
- 1.4k Downloads
Recombinant leptin offers a viable treatment for lipodystrophy (LD) syndromes. However, due to its short plasma half-life, leptin replacement therapy requires at least daily subcutaneous (s.c.) injections. Here, we optimised this treatment strategy in LD mice by using a novel leptin version with extended plasma half-life using PASylation technology.
A long-acting leptin version was prepared by genetic fusion with a 600 residue polypeptide made of Pro, Ala and Ser (PASylation), which enlarges the hydrodynamic volume and, thus, retards renal filtration, allowing less frequent injection. LD was induced in C57BL/6J mice by feeding a diet supplemented with conjugated linoleic acid (CLA). Chronic and acute effects of leptin treatment were assessed by evaluating plasma insulin levels, insulin tolerance, histological liver sections, energy expenditure, energy intake and body composition.
In a cohort of female mice, 4 nmol PAS-leptin (applied via four s.c. injections every 3 days) successfully alleviated the CLA-induced LD phenotype, which was characterised by hyperinsulinaemia, insulin intolerance and hepatosteatosis. The same injection regimen had no measurable effect when unmodified recombinant leptin was administered at an equivalent dose. In a cohort of LD males, a single s.c. injection of PAS-leptin did not affect energy expenditure but inhibited food intake and promoted a shift in fuel selection towards preferential fat oxidation, which mechanistically substantiates the metabolic improvements.
The excellent pharmacological properties render PASylated leptin an agent of choice for refining both animal studies and therapeutic strategies in the context of LD syndromes and beyond.
KeywordsConjugated linoleic acid Fuel selection Leptin Lipodystrophy Metabolic rate PASylation Therapeutic protein
Conjugated linoleic acid
Respiratory exchange ratio
Lipodystrophies (LD) comprise a heterogeneous set of rare metabolic syndromes, either acquired or inherited in nature, which are characterised by a partial or generalised lack of adipose tissue . In LD patients, the major functions of adipose tissue (i.e. storage of energy as triacylglycerols and release of adipokine hormones, such as leptin and adiponectin, to control energy and glucose homeostasis) are hampered [2, 3]. The limited storage capacity of adipose tissue leads to an ectopic fat deposition predominantly in the liver, pancreas and muscle. In addition, adipose tissue paucity causes diminished endocrine activity. In particular, leptin, with its pleiotropic functions, is a critical endocrine factor for the adequate regulation of glucose homeostasis and energy balance [4, 5]. An option for LD therapy is the administration of leptin. Indeed, leptin replacement therapy has been shown to improve glucose and lipid homeostasis, as well as fatty liver disease, in several subtypes of LD [6, 7].
Due to its molecular mass of only 16 kDa, leptin is quickly eliminated from the blood by renal filtration [8, 9]. Thus, leptin must be administered at least on a day-to-day basis to achieve therapeutic efficacy. Plasma half-life extension offers a potent strategy to overcome the limitations of most biologics with poor pharmacokinetic properties . Recently, we developed a novel leptin version by fusing a polypeptide comprising 600 Pro, Ala and Ser (PAS) residues to the N-terminus of the murine protein . The PAS moiety adopts a random coil conformation and expands the average diameter of the fusion protein beyond the pore size of the kidney filtration barrier [11, 12, 13].
Previous experiments in C57BL/6J mice demonstrated a much prolonged plasma half-life, from around 30 min for the unmodified leptin to 20 h for PAS-leptin . In a subsequent study with obese leptin-deficient Lep ob/ob mice, a dose of only ∼16 nmol PAS-leptin (applied via four injections over 20 days) sufficiently induced a weight loss of >40% and alleviated glucose intolerance and hepatic steatosis . These superior characteristics of PAS-leptin are further highlighted by comparison with previous studies where a 25-fold amount of unmodified leptin (∼400 nmol), with daily injections, was required to achieve similar effects [15, 16].
An established method for inducing LD in mice is feeding a diet supplemented with conjugated linoleic acid (CLA) [17, 18, 19]. In CLA fed mice, we compared the efficacy of unmodified and PASylated leptin to alleviate hepatic steatosis and insulin intolerance, and explored the acute effect of PAS-leptin on energy balance.
Preparation of recombinant murine leptin and PAS-leptin
Animals and experimental design
All experiments were conducted with permission from the District Government of Upper Bavaria, Germany (License no. 55.2-1-54-2532-183-11) in a specific pathogen-free animal facility. C57BL/6J mice, obtained from an in-house breeding colony (Kleintierforschungszentrum Weihenstephan, TU München, Freising, Germany), were maintained at 22°C and relative humidity of 55% under light/dark (12 h/12 h) regulated conditions. From the age of 8 weeks onwards, all mice received a purified control diet (CD) containing 5% wt/wt soy oil (no. S5745-E702; Ssniff, Soest, Germany). Two weeks later, all mice were transferred to single cages and LD was induced by CLA feeding. The CLA diet contained 3.5% wt/wt soy oil and 1.5% wt/wt tonalin (TG 80; BASF, Lampertheim, Germany) as CLA source. Tonalin contains 80% vol./vol. CLA with a 50:50 ratio of the two active C18:2 CLA isomers c9,t11 and t10,c12. The CD and CLA diets had the same energy content of 17.4 kJ/g and assimilation efficiencies of 90% (unpublished observations from the authors F. Bolze, A. Bast and M. Klingenspor). After 3 weeks of CLA feeding, mice were body weight matched and injected either with PBS, unmodified leptin or PAS-leptin, while CLA feeding was continued. In Cohort I and II, the injection start was defined as ‘day 0’.
Over 11 days, female mice received four s.c. injections of leptin or PAS-leptin (50 pmol/g per injection; aiming at a peak plasma concentration [Cmax] of 250–300 nmol/l), or a volume of ∼80 μl PBS every 72 h (50 pmol corresponds to 0.85 μg leptin and 3.35 μg PAS-leptin). At day 5 (48 h after the second injection) insulin levels were assessed. Insulin tolerance was measured at day 8 (48 h after the third injection). At day 11 (48 h after the fourth injection) mice were dissected.
Male mice received one s.c. injection of 50 pmol/g PAS-leptin or ∼80 μl PBS. The acute effect of PASylated leptin on energy balance was assessed by parallel measurements of energy intake and energy expenditure for 48 h.
Plasma insulin and leptin quantification and insulin tolerance test
In Cohort I, insulin levels were analysed at day 5 after 6 h fasting using a murine insulin ELISA (Mercodia, Uppsala, Sweden). At day 8, mice were fasted for 6 h and received an intraperitoneal injection of 0.45 U/kg human insulin (Insuman Rapid; Sanofi-Aventis, Frankfurt/Main, Germany). Blood was sampled from a small incision in the tail tip. Glucose levels were quantified with a Freestyle Lite glucometer (Abott, Wiesbaden, Germany).
In a separate cohort of male C57BL/6J mice, plasma leptin levels were measured at the end of a 3 week CLA feeding period, using a murine leptin ELISA (Biovendor, Kassel, Germany)
In Cohort II, energy expenditure was assessed in an open flow respirometry system (TSE systems, Bad Homburg, Germany). One day prior to the measurement, mice were placed in metabolic cages equivalent to the regular home cage used during the induction phase. Air was drawn from these cages (flow 0.7 l/min), dried in a cooling trap and analysed for O2 and CO2 concentrations in 9 min intervals. Respiratory exchange ratio (RER) and heat production were calculated as described previously . Cumulative metabolic rate (MR) represents heat production over 48 h of the measurement. For data evaluation, cumulative MR was adjusted to the covariate lean mass using the relation MR = 2.52 × lean mass + 39.1 (r 2 = 0.271, p < 0.05) . For more precise analysis of substrate oxidation, five arbitrary RER range bins were defined and the duration for which mice maintained their RER within these ranges was computed. The lowest two bins reflected preferential lipid oxidation (0.70–0.75 and 0.76–0.81), whereas the higher ones indicated more carbohydrate oxidation (0.88–0.93 and 0.94–1.00). Accordingly, balanced fuel selection was indicated by the intermediate range (0.82–0.87). Carbohydrate and fatty acid oxidation were determined from RER and cumulative MR .
Energy intake, body mass and body composition
Food intake was quantified by weighing of the food racks, and converted to kJ for assessment of energy intake. In the induction phase, energy intake for both cohorts was assessed weekly. During the treatment phase, energy intake for Cohort I was determined every 3 days and, for Cohort II, 48 h after the injection. Body mass, total body fat and total body lean mass (LF50H TD‐NMR Analyzer; Bruker Biospin, Rheinstetten, Germany) were repeatedly measured (days for Cohort I: −21, −14, −7, 0, 7, 11 and for Cohort II: −21, −14, −7, −1).
In Cohort I, hepatosteatosis was evaluated via inspection of haematoxylin/eosin (HE) stained sections, by three ‘blinded’ collaborators utilising a light microscopy histoscore ranging from 0 (no steatosis) to 4 (severe steatosis). Hepatic triacylglycerol content was assayed with an enzymatic test based on the GPO/PAP method (Triglycerides Liquicolor; Human, Wiesbaden, Germany; see electronic supplementary material [ESM]). Plasma concentrations of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using commercially available colourimetric kits (ALTPM and ASTPM; Roche Diagnostics, Indianapolis, IN, USA).
Data handling and statistics
The design included six to seven mice per group. In Cohort I some variables could not be assessed in all mice due to experimental constraints, which may represent a potential limitation of this study. Hypoglycaemia after 6 h fasting prevented insulin tolerance tests in two mice, and blood sample volume was insufficient for insulin ELISA in two cases. After the CLA induction phase, one growth-retarded mouse and one AST value were excluded from statistical analysis based on Grubb’s outlier test. Data are expressed as means ± SD. Statistical significance of normally distributed data was tested by either unpaired t tests or one-way ANOVA with subsequent multiple comparisons using Sigmaplot 12.5 (Systat Software, Erkrath, Germany). Non-normally distributed data were log10-transformed.
CLA feeding induces LD in C57BL/6J mice
Feeding a CLA-diet for 3 weeks induced LD in both sexes, as demonstrated by a loss in total body fat; compared with the CD-fed groups, body fat mass was reduced by 54% in Cohort I and 38% in Cohort II of CLA-fed (LD) mice (ESM Table 1 and ESM Fig. 1). Also, CLA feeding resulted in hypoleptinaemia (CD: 122 ± 70 pmol/l vs CLA: 44 ± 24 pmol/l, p < 0.001), as seen in a separate cohort of male mice with comparable body fat reduction (data not shown). Body mass was similar in CD- and CLA-fed mice since fat loss was accompanied by a gain in lean mass in the CLA-groups (ESM Table 1 and ESM Fig. 1). Notably, energy density of fat tissue is nearly twice that of lean tissue. Hence, this shift in body composition should be associated with a loss in total body energy content, indicating that CLA induced a negative energy balance. Therefore, CLA most likely accelerated energy expenditure, since energy intake was similar between CD- and CLA-fed mice (ESM Table 1 and ESM Fig. 2).
Repeated PAS-leptin injections normalise insulin intolerance and hepatic steatosis
Leptin treatment effects on body mass, body composition, organ weights and liver enzymes in LD Cohort I
PBS (n = 7)
PBS (n = 5)
Leptin (n = 6)
PAS-leptin (n = 6)
Body mass (g)
20.3 ± 1.4
20.2 ± 0.7
20.1 ± 0.4
18.9 ± 1.1
Lean mass (g)
14.9 ± 1.1
15.8 ± 0.3
16.1 ± 0.6
15.5 ± 1.1
Fat mass (g)
2.82 ± 0.36a
1.46 ± 0.26b
1.55 ± 0.18b
0.97 ± 0.30c
Inguinal WAT (mg)
214 ± 35a
44 ± 6b
48 ± 9b
45 ± 6b
Gonadal WAT (mg)
215 ± 58a
114 ± 35b
119 ± 25b
46 ± 16c
Interscapular BAT (mg)
58 ± 8a
14 ± 1b
15 ± 2b
13 ± 3b
98 ± 0.018
102 ± 27
85 ± 12
90 ± 11
125 ± 45
354 ± 231
281 ± 251
193 ± 70
40 ± 24a
217 ± 132b
198 ± 137b
118 ± 57b
Compared with CLA/PBS and CLA/leptin groups, PAS-leptin led to a loss of around 0.5 g in total body fat in LD mice (Table 1) which was contributed by reductions in liver weight by ∼0.5 g (Fig. 2a) and in gonadal adipose tissue (Table 1). Relative to the other CLA-fed groups, the PAS-leptin group had a significantly lower average daily energy intake during the treatment period (CLA/PBS mice: 44.8 ± 3.6 kJ/day, CLA/Leptin mice: 48.3 ± 2.5 kJ/day, CLA/PAS-leptin mice: 41.8 ± 2.7 kJ/day; p < 0.05).
A single PAS-leptin injection has no effect on MR but promotes fat utilisation
PASylation has allowed the design of biopharmaceuticals with tailored pharmacological properties to improve animal studies, as well as therapies and diagnosis of various diseases [13, 23, 24]. Here, we explored the efficacy of a new long-acting leptin version prepared via PASylation in a CLA-induced lipodystrophic (LD) mouse model. The supremacy of PAS-leptin was demonstrated by efficient normalisation of insulin sensitivity, plasma insulin levels and fatty liver disease. These metabolic improvements are in line with previous reports in which conventional leptin – infused via osmotic pumps – successfully ameliorated LD symptoms in CLA fed mice [18, 19]. The failure of unmodified leptin, with its poor pharmacokinetic characteristics, to induce metabolic benefits was not surprising at the low dose applied and the rather long injection intervals. Conversely, the treatment regimen was perfectly suited for PAS-leptin and suggests benefits in clinical settings. It is worth mentioning that not only LD patients should profit from PAS-leptin; several preclinical studies in mice have suggested that individuals suffering from type 1 and type 2 diabetes or neurodegenerative diseases may also benefit from optimised leptin analogues [25, 26, 27].
No previous study has focused on the acute effect of leptin on energy balance in LD mice. PAS-leptin shifted fuel selection towards lipid oxidation. This could have been mediated either by direct stimulation of lipid metabolism or by an inhibitory effect on energy intake [28, 29, 30]. Indeed, the latter phenomenon was confirmed in both cohorts used in this study. Accordingly, food intake did not provide sufficient calories, thus promoting the oxidation of endogenous fat stores. As a consequence, body fat was decreased in Cohort I. The majority of this body fat loss can be attributed to the reduction of liver fat, thus linking the increased fat utilisation observed during indirect calorimetry to the correction of a pathological hallmark of LD. Apart from decreased energy intake, a direct impact of PAS-leptin on lipid utilisation, which would further accelerate the elimination of ectopic fat, cannot be excluded. In fact, in the genetic aP2-SREBP-1c LD mouse model a 30% food restriction was not as effective as leptin infusion, which supports both a direct and indirect role of leptin on the amelioration of hepatosteatosis .
Low plasma leptin levels are known to mediate metabolic suppression [4, 32]. Counterintuitively, hypoleptinaemia (induced by CLA feeding) was associated with increased cumulative MR. As CLA did not affect energy intake, elevated cumulative MR is obviously a valid explanation for the reduction in total body energy content indicated by lower body fat of LD mice. Likewise, others have reported an increase in energy expenditure during CLA feeding in LD mice [33, 34, 35, 36]. However, some of these findings must be critically re-evaluated due to pitfalls in the use of mass-specific ratios to normalise for differences in body weight and body composition [34, 35]. Mass-specific ratios can lead to over- or underestimations of MR . By state-of-the-art data analysis, we demonstrate that increased cumulative MR in LD mice was due to the higher lean mass induced by CLA feeding, since adjustment for variation in lean mass either removed or attenuated the significant differences. Our analysis of cumulative MR revealed no explicit tachymetabolic effect of PAS-leptin. In CLA/PAS-leptin mice, lean mass-adjusted cumulative MR remained significantly elevated compared with CD/PBS mice but was not different from the CLA/PBS group. At the given difference of less than 5% between CLA/PBS and CD/PAS-leptin mice, a power calculation indicates that the sample size must be increased to >20 mice per group in order to verify whether PAS-leptin may stimulate energy expenditure in LD mice, hence leaving this question for future study.
In conclusion, a remarkably low dose of ~4 nmol long-acting PASylated leptin alleviated insulin intolerance and hepatosteatosis in LD mice. PAS-leptin altered fuel selection at least partially by a reduction of energy intake but may also operate through direct stimulation of sympathetic nervous system activity  or peripheral effects on lipolysis [28, 29, 30]. In concert with our previous reports [11, 14], these findings underline the superiority of PAS-leptin in preclinical research and its potential for therapeutic application.
MH was supported by a European Research Council (ERC) grant (LiverCancerMech).
Duality of interest
AS and MS are shareholders of XL-protein GmbH.
FB designed the experiments, acquired and analysed data and drafted the manuscript. AB, SM, VM, DY, NR, MS and AZ acquired data and drafted the manuscript. MH contributed to the study design and drafted the manuscript. AS and MK drafted the manuscript, critically revised the text and contributed to the study design and data analysis. All authors approved the final version of the text. FB is responsible for the integrity of the work as a whole.
- 27.Perez-Gonzalez R, Alvira-Botero MX, Robayo O et al (2014) Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in APP/PS1 mice. Gene Ther 21:298–308Google Scholar
- 30.Huang W, Dedousis N, Bandi A, Lopaschuk GD, O'Doherty RM (2006) Liver triglyceride secretion and lipid oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology 147:1480–1487Google Scholar